Egfr-tki resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2428-2434

  Nakagawa, Takayuki ^a,d   Takeuchi, Shinji ^a   Yamada, Tadaaki ^a   Ebi, Hiromichi ^a   Sano, Takako ^a   Nanjo, Shigeki ^a   Ishikawa, Daisuke ^a   Sato, Mitsuo ^b   Hasegawa, Yoshinori ^b   Sekido, Yoshitaka ^c   Yano, Seiji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; HISTONE DEACETYLASE; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOLID TUMOR; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MUTATION; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876994464     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3479     Document Type: Article

References (20)

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
2. Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74.
3. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26.
4. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87.
5. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A commonBIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521-8.
6. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: A novelmember of the Bcl-2 family that promotes apoptosis. EMBO J 1998;17:384-95.
7. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17: 393-403.
8. Heath-Engel HM, Shore GC. Regulated targeting of Bax and Bak to intracellular membranes during apoptosis. Cell Death Differ 2006;13: 1277-80.
9. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-79.
10. Fukazawa H, Noguchi K, Masumi A, Murakami Y, Uehara Y. BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors. Mol Cancer Ther 2004;3:1281-8.
11. Liu JW, Chandra D, Tang SH, Chopra D, Tang DG. Identification and characterization of Bimgamma, a novel proapoptotic BH3-only splice variant of Bim. Cancer Res 2002;62:2976-81.
12. FaberAC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011;1:352-65.
13. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
14. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous Tcell lymphoma. Oncologist 2007;12:1247-52.
15. Xargay-Torrent S, Lopez-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, Roue G, et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res 2011;17:3956-68.
16. Delcuve GP, Khan DH, Davie Jr. Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors. Clin Epigenetics 2012;4:5.
17. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al.Achromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
18. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-50.
19. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30:2248-55.
20. Cetin Z, Ozbilim G, Erdogan A, Luleci G, Karauzum SB. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol 2010;27:853-60.